CN110049764A - 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 - Google Patents

用于治疗肾脏疾病或病症的联苯磺酰胺化合物 Download PDF

Info

Publication number
CN110049764A
CN110049764A CN201780076280.6A CN201780076280A CN110049764A CN 110049764 A CN110049764 A CN 110049764A CN 201780076280 A CN201780076280 A CN 201780076280A CN 110049764 A CN110049764 A CN 110049764A
Authority
CN
China
Prior art keywords
pharmaceutical composition
subject
compound
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780076280.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·科梅尔斯
A·施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Inc
Original Assignee
Retrophin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrophin Inc filed Critical Retrophin Inc
Priority to CN202210441043.8A priority Critical patent/CN114788823A/zh
Priority to CN202311092711.1A priority patent/CN116983302A/zh
Priority to CN202311094233.8A priority patent/CN117017985A/zh
Priority to CN202311093985.2A priority patent/CN117085013A/zh
Publication of CN110049764A publication Critical patent/CN110049764A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780076280.6A 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 Pending CN110049764A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202210441043.8A CN114788823A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311092711.1A CN116983302A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311094233.8A CN117017985A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311093985.2A CN117085013A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US62/407,860 2016-10-13
US201662423079P 2016-11-16 2016-11-16
US62/423,079 2016-11-16
PCT/US2017/056538 WO2018071784A1 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202210441043.8A Division CN114788823A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311094233.8A Division CN117017985A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311093985.2A Division CN117085013A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311092711.1A Division CN116983302A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Publications (1)

Publication Number Publication Date
CN110049764A true CN110049764A (zh) 2019-07-23

Family

ID=60191503

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201780076280.6A Pending CN110049764A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311093985.2A Pending CN117085013A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311092711.1A Pending CN116983302A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202210441043.8A Pending CN114788823A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311094233.8A Pending CN117017985A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202311093985.2A Pending CN117085013A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311092711.1A Pending CN116983302A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202210441043.8A Pending CN114788823A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN202311094233.8A Pending CN117017985A (zh) 2016-10-13 2017-10-13 用于治疗肾脏疾病或病症的联苯磺酰胺化合物

Country Status (10)

Country Link
US (5) US20190262317A1 (https=)
EP (1) EP3525784B1 (https=)
JP (4) JP2019530713A (https=)
KR (4) KR20240162167A (https=)
CN (5) CN110049764A (https=)
AU (3) AU2017341825B2 (https=)
BR (1) BR112019007576A2 (https=)
CA (1) CA3039819A1 (https=)
MA (1) MA46524A (https=)
WO (1) WO2018071784A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113272013A (zh) * 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102902972B1 (ko) * 2018-10-04 2025-12-22 트래버르 테라퓨틱스, 인코포레이티드 Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
CA3124127A1 (en) * 2018-12-21 2020-06-25 Travere Therapeutics, Inc. Amorphous sparsentan compositions
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
CN117836294A (zh) * 2021-08-26 2024-04-05 上海翰森生物医药科技有限公司 含芳环类生物拮抗剂、其制备方法和应用
IL312723A (en) * 2021-12-28 2024-07-01 Alchemedicine Inc Compound, angiotensin ii type 1 receptor antagonist, and pharmaceutical composition
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
WO2024249509A1 (en) 2023-05-31 2024-12-05 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
WO2025064688A1 (en) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan for treating immunoglobulin a nephropathy (igan)
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308536A (zh) * 1998-07-06 2001-08-15 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
CN104107176A (zh) * 2009-03-31 2014-10-22 利亘制药公司 治疗高血压和糖尿病肾病的二苯基磺酰胺内皮素和血管紧张素ii受体激动剂的口服制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
DE60030764T2 (de) 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
MA39838B1 (fr) * 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
KR102902972B1 (ko) 2018-10-04 2025-12-22 트래버르 테라퓨틱스, 인코포레이티드 Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308536A (zh) * 1998-07-06 2001-08-15 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
CN104107176A (zh) * 2009-03-31 2014-10-22 利亘制药公司 治疗高血压和糖尿病肾病的二苯基磺酰胺内皮素和血管紧张素ii受体激动剂的口服制剂

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DONALD E. KOHAN等: "Endothelin and endothelin antagonists in chronic kidney disease", 《KIDNEY INT.》 *
LOUIS-PHILIPPE LAURIN: "The Role of Calcineurin Inhibitor Therapy in Treatment of Primary Focal Segmental Glomerulosclerosis", 《MASTER OF SCIENCE IN EPIDEMIOLOGY》 *
RADKO KOMERS等: "Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease", 《AM J PHYSIOL REGUL INTEGR COMP PHYSIOL》 *
SHELDON TOBE等: "Endothelin Receptor Antagonists: New Hope for Renal Protection?", 《CURR HYPERTENS REP》 *
TRAVERE THERAPEUTICS,INC.: "NCT01613118（https://clinicaltrials.gov/ct2/show/NCT01613118?term=duet+RE-）", 《CLINICALTRIALS》 *
YUICHI IKEDA等: "Next Generation ARBs", 《INTERNATIONAL HEART JOURNAL》 *
李明亚主编: "《临床药物治疗学》", 31 August 2015, 中国医药科技出版社 *
桂永浩主编: "《小儿内科学高级教程》", 31 January 2014, 人民军医出版社 *
邹万忠主编: "《肾活检病理诊断图鉴》", 31 March 2000, 人民卫生出版社 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113272013A (zh) * 2019-12-17 2021-08-17 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
US11491137B2 (en) 2019-12-17 2022-11-08 Chinook Therapeutics, Inc. Methods of improving renal function
CN116327758A (zh) * 2019-12-17 2023-06-27 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
US11998526B2 (en) 2019-12-17 2024-06-04 Chinook Therapeutics, Inc. Methods of improving renal function
US12121509B2 (en) 2019-12-17 2024-10-22 Chinook Therapeutics, Inc. Methods of improving renal function
US12370174B2 (en) 2019-12-17 2025-07-29 Chinook Therapeutics, Inc. Methods of improving renal function
US12521369B2 (en) 2019-12-17 2026-01-13 Chinook Therapeutics, Inc. Methods of improving renal function
US12582631B2 (en) 2019-12-17 2026-03-24 Chinook Therapeutics, Inc. Methods of improving renal function

Also Published As

Publication number Publication date
KR102528435B1 (ko) 2023-05-03
US20200281901A1 (en) 2020-09-10
CN117085013A (zh) 2023-11-21
KR20220132030A (ko) 2022-09-29
KR20230066644A (ko) 2023-05-16
CN114788823A (zh) 2022-07-26
US20250325522A1 (en) 2025-10-23
JP2022141802A (ja) 2022-09-29
WO2018071784A1 (en) 2018-04-19
EP3525784A1 (en) 2019-08-21
EP3525784B1 (en) 2026-01-28
KR20190077348A (ko) 2019-07-03
AU2017341825A1 (en) 2019-04-11
JP2019530713A (ja) 2019-10-24
CN117017985A (zh) 2023-11-10
AU2025271121A1 (en) 2025-12-18
US20250325523A1 (en) 2025-10-23
US20210196688A1 (en) 2021-07-01
CA3039819A1 (en) 2018-04-19
US10864197B2 (en) 2020-12-15
CN116983302A (zh) 2023-11-03
BR112019007576A2 (pt) 2019-07-02
AU2017341825B2 (en) 2023-06-01
AU2023219839A1 (en) 2023-09-07
JP2025060754A (ja) 2025-04-10
MA46524A (fr) 2019-08-21
KR20240162167A (ko) 2024-11-14
AU2023219839B2 (en) 2025-08-21
US20190262317A1 (en) 2019-08-29
JP2022137245A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
US20250325523A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Traville treatment Co.

Address before: California, USA

Applicant before: Retrophin, Inc.

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20190723

RJ01 Rejection of invention patent application after publication